Sun Pharma Advanced Research Company Ltd Share Price
As on 13 June 2026 at 02:35 IST
Sun Pharma Advanced Research Company Q1 FY26 Results:
The company reported a loss of ₹51.9 crores for the period in Q1 FY26, improving from a loss of ₹95.9 crores in Q1 FY25. Total income for the quarter increased by 2.2% year-on-year to ₹18.8 crores, from ₹18.4 crores.
About Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd. (SPARC) emerges as a dynamic clinical-stage biopharmaceutical enterprise. The company is dedicated to developing groundbreaking therapeutics that elevate global healthcare standards. Established in 2007 through a strategic demerger from Sun Pharmaceutical Industries Limited, SPARC has its headquarters in Mumbai, Maharashtra. The company has positioned itself as an innovative force in the biopharmaceutical landscape. SPARC concentrates its R&D efforts on oncology, neurology, and immunology. The company's ambitious pipeline showcases a commitment to addressing complex medical challenges through potentially transformative treatments. Noteworthy products also include Vodobatinib and Vibozilimod. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
21.17%
Over 6 Months
48.66%
Over 1 Year
23.11%
Over 3 Years
6.64%
Sun Pharma Advanced Research Company Ltd Summary
Close ₹204.11
Open ₹204.99
High ₹213
Low ₹202.19
Volume 22,62,997
Net Turnover (in Cr) ₹47
52Wk High ₹248.75
52Wk Low ₹108
52Wk High / Low
108
248.75
Sun Pharma Advanced Research Company Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹6,623.81
EPS (TTM) 48.21
Book Value (BV) 41.09
Div. Yield -
P/E (TTM) 4.27
Price/Book Value 4.96
Delivery % 31.10 %
Face Value 1
Key Ratios
PE Ratio -
PB Ratio -21.76
EV to Sales 70.60
PEG Ratio -
ROA -297.71
ROE -
Debt-Equity -
Net Profit Margin -481.01
Operating Profit Margin -453.50
Sun Pharma Advanced Research Company Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total Revenue | 73.56 | 105.01 | 249.66 |
| Total Expenses | 416.34 | 491.85 | 472.24 |
| Profit Before Tax | -342.78 | -386.83 | -222.58 |
| Profit After Tax | -342.51 | -387.21 | -222.58 |
| Operating Profit After Depreciation | -333.74 | -385.14 | -214.95 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Fixed Assets | 152.35 | 150.06 | 130.88 |
| Total Non Current Assets | 309.34 | 245.66 | 375.16 |
| Total Current Assets | 26.20 | 269.39 | 454.96 |
| Total Assets | 335.53 | 515.04 | 830.13 |
| Total Shareholder's Fund | -216.95 | 125.76 | 512.78 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Cash From Operating Activities | -360.29 | -429.19 | -69.12 |
| Net Cash Used In Investing Activities | 157.67 | 391.53 | -548.28 |
| Net Cash Used In Financing Activities | 199.26 | 42.41 | 616.76 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 73.56 | 105.01 | 249.66 | 144.09 | 258.37 |
| Total Expenses | 418.78 | 493.12 | 472.24 | 347.49 | 409.51 |
| Profit Before Tax | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 |
| Profit After Tax | -345.22 | -388.11 | -222.58 | -203.40 | -151.14 |
| Operating Profit After Depreciation | -336.32 | -386.45 | -214.95 | -190.07 | -140.49 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 148.92 | 145.17 | 130.88 | 114.51 | 90.56 |
| Total Non Current Assets | 304.02 | 239.93 | 375.16 | 208.93 | 166.58 |
| Total Current Assets | 25.26 | 246.41 | 454.96 | 71.15 | 63.11 |
| Total Assets | 329.28 | 486.33 | 830.13 | 280.08 | 229.69 |
| Total Shareholder's Fund | -220.62 | 124.86 | 512.78 | 31.23 | -168.25 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -362.41 | -429.43 | -69.12 | -208.23 | -151.90 |
| Net Cash Used In Investing Activities | 157.66 | 391.11 | -548.28 | -29.17 | 1.56 |
| Net Cash Used In Financing Activities | 200.88 | 42.80 | 616.76 | 229.32 | 159.28 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,853.22 | 8.45 | 7.86 | 9.64 | 27.19 |
| Total Expenses | 80.02 | 65.09 | 73.58 | 61.72 | 80.37 |
| Profit Before Tax | 1,760.96 | -80.35 | -75.79 | -51.81 | -60.67 |
| Profit After Tax | 1,761.34 | -80.42 | -75.85 | -51.87 | -59.77 |
| Operating Profit after Depreciation | 1,775 | -56.64 | -65.71 | -42.94 | -53.18 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 1,853.22 | 8.45 | 7.86 | 9.64 | 27.19 |
| Total Expenses | 80.28 | 65.32 | 73.75 | 61.97 | 81.11 |
| Profit Before Tax | 1,760.70 | -80.57 | -75.97 | -52.03 | -60.98 |
| Profit After Tax | 1,760.70 | -80.57 | -75.97 | -52.03 | -60.98 |
| Operating Profit after Depreciation | 1,774.74 | -56.87 | -65.88 | -43.31 | -53.92 |
Sun Pharma Advanced Research Company Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 199.87
S2 195.62
S3 189.06
Pivot 206.43
R1 210.68
R2 217.24
R3 221.49
Moving Average
20 SMA 200.46
50 SMA 166.85
100 SMA 147.40
200 SMA 142.33
Sun Pharma Advanced Research Company Ltd Corporate Actions
No available data
Sun Pharma Advanced Research Company Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Sun Pharma Advanced Research Company Ltd Top Mutal Funds Invested
Sun Pharma Advanced Research Company Ltd News
Sun Pharma Advanced Research Company raises Rs 150 cr via warrant issuance
19 May 2026, 03:08 pm
Sun Pharma Advanced Research Company to conduct board meeting
On 18 May 2026
12 May 2026, 12:36 pm
Sun Pharma Advanced Research Company sells its Priority Review Voucher for USD 195 million
30 Apr 2026, 09:47 am
Sun Pharma Advanced Research Company announces change in senior management
With effect from 31 March 2026
03 Apr 2026, 01:04 pm
Sun Pharma Advanced Research Company announces board meeting date
On 9 February 2026
04 Feb 2026, 11:53 am
Sun Pharma Advanced Research Company Ltd Stock Analysis
- Annual revenue for Sun Pharma Advanced Research Company Ltd decreased by 29.96% to ₹73.56 crore in FY 2025 from ₹105.01 crore in FY 2024.
- Annual Net Profit for Sun Pharma Advanced Research Company Ltd decreased by 11.05% to ₹-345.22 crore in FY 2025 from ₹-388.11 crore in FY 2024.
- Promoter Shareholding in Sun Pharma Advanced Research Company Ltd remains unchanged by 0.00% in the most recent quarter, from 65.67% in May 2026 to 65.67% in May 2026.
- Sun Pharma Advanced Research Company Ltd delivered a 1-year return of 23.11% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Sun Pharma Advanced Research Company Ltd share price moved up by 2.35% from its previous close of INR ₹204.11. The latest Sun Pharma Advanced Research Company Ltd share price is INR ₹208.90.
- Sun Pharma Advanced Research Company Ltd share price today has been at a low of 205.81 and a high of 211. Over the past 52 weeks, the Sun Pharma Advanced Research Company Ltd share price has seen a low of 108 and a high of 248.75.
About Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd. (SPARC) emerges as a dynamic clinical-stage biopharmaceutical enterprise. The company is dedicated to developing groundbreaking therapeutics that elevate global healthcare standards. Established in 2007 through a strategic demerger from Sun Pharmaceutical Industries Limited, SPARC has its headquarters in Mumbai, Maharashtra. The company has positioned itself as an innovative force in the biopharmaceutical landscape.
SPARC concentrates its R&D efforts on oncology, neurology, and immunology. The company's ambitious pipeline showcases a commitment to addressing complex medical challenges through potentially transformative treatments. Noteworthy products include Vodobatinib, which targets neurodegenerative conditions like Parkinson's and Alzheimer's diseases. The company offers SBO-154 for multiple tumour treatments, which shows promise in managing psoriasis and atopic dermatitis.
The top promoter of SPARC is Shanghvi Finance Private Limited, which holds 42.28% of the total equity. The company may not dominate the global biopharmaceutical sector. However, it has carved out a significant niche in the clinical-stage research environment.
The company's leadership is characterized by seasoned professionals, with Dilip S Shanghvi serving as the Chairman & Non-Exe. Director, while T Rajamannar holds the position of Non-Executive Director. Apart from them, there are other managerial promoters who have contributed to the success of the company. They are –
SPARC's fundamental mission transcends mere commercial objectives. It focuses on developing sophisticated therapeutic solutions that can potentially revolutionize patient care. By concentrating on complex medical conditions and investing in cutting-edge research, the company demonstrates a profound commitment to advancing medical science and improving global health outcomes.
Through its strategic research approach and focus on innovative therapeutics, Sun Pharma Advanced Research Company Ltd. is a promising contributor to the evolution of modern medical treatment methodologies.
SPARC began its journey with a clear vision: to leverage science and technology to develop novel therapies. The company's foundation was built on the strong legacy of Sun Pharmaceutical Industries. This backing provided SPARC with the necessary resources and expertise to embark on its innovative path. From the outset, SPARC is committed to rigorous research and development (R&D), emphasizing quality and efficacy in its drug development process.
SPARC has focused its efforts on three primary therapeutic areas: oncology, neurology, and immunology. In oncology, the company is developing treatments for various cancers, aiming to offer more effective and less toxic options for patients. In neurology, SPARC is working on drugs for neurodegenerative diseases like Parkinson's and Alzheimer's, striving to improve the quality of life for patients with these debilitating conditions. In immunology, the company is developing therapies for autoimmune diseases, which are becoming increasingly prevalent worldwide.
One of SPARC's key innovations has been in the area of drug delivery systems. The company has developed several advanced drug delivery technologies that enhance the efficacy and safety of medications. For instance, SPARC's platform for controlled-release formulations allows for precise dosing and sustained drug release. This reduces the frequency of administration and improves patient compliance. These innovations demonstrate SPARC's commitment to developing new drugs. It also shows the company's vision to improve the way existing drugs are delivered.
Quality and compliance are central to SPARC's operations. The company adheres to stringent regulatory standards. This ensures that its products meet the highest levels of safety and efficacy. SPARC's commitment to quality is evident in its manufacturing facilities and rigorous quality control processes.
SPARC has established strategic collaborations with leading academic institutions and pharma companies. These partnerships enhance SPARC's R&D capabilities. It also accelerates the development of new therapies. Also, collaborating with external experts allows SPARC to leverage diverse expertise and resources. This fosters innovation and expedites the journey from discovery to market.
The journey of innovation is not without challenges. SPARC has faced various hurdles, including competitive pressures and the inherent uncertainties of drug development. However, the company's ability to adapt and innovate has been key to its success. By staying agile and responsive to changing market dynamics, SPARC has continued to make progress in its mission to transform patient care through innovative therapies.
Looking ahead, SPARC aims to further strengthen its position in the biopharmaceutical sector. The company is committed to investing in cutting-edge research to leverage its scientific expertise to develop breakthrough treatments. Additionally, SPARC plans to expand its global presence, bringing its innovative therapies to patients around the world.
SPARC concentrates its R&D efforts on oncology, neurology, and immunology. The company's ambitious pipeline showcases a commitment to addressing complex medical challenges through potentially transformative treatments. Noteworthy products include Vodobatinib, which targets neurodegenerative conditions like Parkinson's and Alzheimer's diseases. The company offers SBO-154 for multiple tumour treatments, which shows promise in managing psoriasis and atopic dermatitis.
The top promoter of SPARC is Shanghvi Finance Private Limited, which holds 42.28% of the total equity. The company may not dominate the global biopharmaceutical sector. However, it has carved out a significant niche in the clinical-stage research environment.
The company's leadership is characterized by seasoned professionals, with Dilip S Shanghvi serving as the Chairman & Non-Exe. Director, while T Rajamannar holds the position of Non-Executive Director. Apart from them, there are other managerial promoters who have contributed to the success of the company. They are –
- Robert J Spiegel
- Sudhir V Valia
- Bhavna Doshi
SPARC's fundamental mission transcends mere commercial objectives. It focuses on developing sophisticated therapeutic solutions that can potentially revolutionize patient care. By concentrating on complex medical conditions and investing in cutting-edge research, the company demonstrates a profound commitment to advancing medical science and improving global health outcomes.
Through its strategic research approach and focus on innovative therapeutics, Sun Pharma Advanced Research Company Ltd. is a promising contributor to the evolution of modern medical treatment methodologies.
SPARC's Journey in Medical Innovation
Sun Pharma Advanced Research Company Ltd. (SPARC) has been at the forefront of medical innovation. Established in 2007 after a demerger from Sun Pharmaceutical Industries Limited, it has made significant strides in the biopharmaceutical sector. The company focuses on developing innovative therapeutics that improve the standards of care for patients worldwide. Its work spans oncology, neurology, and immunology, addressing some of the most challenging diseases.SPARC began its journey with a clear vision: to leverage science and technology to develop novel therapies. The company's foundation was built on the strong legacy of Sun Pharmaceutical Industries. This backing provided SPARC with the necessary resources and expertise to embark on its innovative path. From the outset, SPARC is committed to rigorous research and development (R&D), emphasizing quality and efficacy in its drug development process.
SPARC has focused its efforts on three primary therapeutic areas: oncology, neurology, and immunology. In oncology, the company is developing treatments for various cancers, aiming to offer more effective and less toxic options for patients. In neurology, SPARC is working on drugs for neurodegenerative diseases like Parkinson's and Alzheimer's, striving to improve the quality of life for patients with these debilitating conditions. In immunology, the company is developing therapies for autoimmune diseases, which are becoming increasingly prevalent worldwide.
One of SPARC's key innovations has been in the area of drug delivery systems. The company has developed several advanced drug delivery technologies that enhance the efficacy and safety of medications. For instance, SPARC's platform for controlled-release formulations allows for precise dosing and sustained drug release. This reduces the frequency of administration and improves patient compliance. These innovations demonstrate SPARC's commitment to developing new drugs. It also shows the company's vision to improve the way existing drugs are delivered.
Quality and compliance are central to SPARC's operations. The company adheres to stringent regulatory standards. This ensures that its products meet the highest levels of safety and efficacy. SPARC's commitment to quality is evident in its manufacturing facilities and rigorous quality control processes.
SPARC has established strategic collaborations with leading academic institutions and pharma companies. These partnerships enhance SPARC's R&D capabilities. It also accelerates the development of new therapies. Also, collaborating with external experts allows SPARC to leverage diverse expertise and resources. This fosters innovation and expedites the journey from discovery to market.
The journey of innovation is not without challenges. SPARC has faced various hurdles, including competitive pressures and the inherent uncertainties of drug development. However, the company's ability to adapt and innovate has been key to its success. By staying agile and responsive to changing market dynamics, SPARC has continued to make progress in its mission to transform patient care through innovative therapies.
Looking ahead, SPARC aims to further strengthen its position in the biopharmaceutical sector. The company is committed to investing in cutting-edge research to leverage its scientific expertise to develop breakthrough treatments. Additionally, SPARC plans to expand its global presence, bringing its innovative therapies to patients around the world.
FAQ’s
What is the share price of Sun Pharma Advanced Research Company Ltd today?
Sun Pharma Advanced Research Company Ltd share price as on 12 Jun 2026 is ₹ 208.9
What is the Market Cap of Sun Pharma Advanced Research Company Ltd?
The market cap of Sun Pharma Advanced Research Company Ltd stock is ₹6,623.81 Cr.
What is the PE Ratio of Sun Pharma Advanced Research Company Ltd?
The Price to Earnings (P/E) Ratio of Sun Pharma Advanced Research Company Ltd is -
What is the PB Ratio of Sun Pharma Advanced Research Company Ltd?
The Price to Book (P/B) Ratio of Sun Pharma Advanced Research Company Ltd is -21.76
What is the 52 week high of Sun Pharma Advanced Research Company Ltd Share Price?
The 52 week high of Sun Pharma Advanced Research Company Ltd share price stands at ₹248.75
What is the 52 week low of Sun Pharma Advanced Research Company Ltd Share Price?
The 52 week low of Sun Pharma Advanced Research Company Ltd share price stands at ₹108
How can I buy shares of Sun Pharma Advanced Research Company Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Sun Pharma Advanced Research Company Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
